MOTS-c Liver Function Impact: What the Research Shows

What Is MOTS-c and Why Does the Liver Matter?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a short peptide translated from a non-canonical open reading frame inside mitochondrial DNA. Unlike nuclear-encoded peptides, it originates from the mitochondrial genome, making it one of a small class of molecules called mitochondrial-derived peptides (MDPs). The liver is the metabolic clearinghouse of the body, and MOTS-c concentrations in portal circulation are substantially higher than in peripheral blood in rodent models, suggesting the liver is both a primary site of action and a likely source of hepatic MOTS-c secretion.

Why the Liver Is the Central Target

Hepatocytes are among the most mitochondria-dense cells in the body, housing 1,000 to 2,000 mitochondria per cell. Because MOTS-c originates from mitochondrial DNA, its production scales with mitochondrial biogenesis and metabolic stress. During states of caloric excess or insulin resistance, hepatic mitochondria increase reactive oxygen species output, which may suppress endogenous MOTS-c production. This creates a feedback loop: the organ that most needs the peptide produces less of it when metabolic dysfunction is already established.

Lee et al. (Cell Metabolism, 2015) first characterized MOTS-c as an exercise-inducible, insulin-sensitizing peptide that acts primarily through the folate-methionine cycle and AMPK signaling. [1] That original paper used intraperitoneal injection in mice fed a high-fat diet and observed that treated animals showed significantly lower fasting glucose and improved insulin tolerance compared with vehicle controls. Hepatic glucose output, measured by pyruvate tolerance test, fell by roughly 30% in the MOTS-c-treated group. That hepatic glucose suppression is the mechanistic starting point for the liver-specific effects described in the sections below.

The Folate Cycle Connection

MOTS-c inhibits enzymes in the folate cycle, specifically MTHFD2 and SHMT2, inside the mitochondrial matrix. This inhibition reduces the availability of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), an endogenous AMPK activator. The net effect is paradoxical at first glance: MOTS-c initially reduces AICAR synthesis, which transiently lowers AMPK activity, but the downstream consequence in the cytoplasm is a compensatory AMPK phosphorylation surge that ultimately increases net AMPK activity in hepatocytes. This two-step mechanism distinguishes MOTS-c from direct AMPK agonists like metformin and explains why its hepatic effects have a slightly delayed kinetic profile in animal models.

MOTS-c and Hepatic Insulin Resistance

Hepatic insulin resistance is the earliest detectable metabolic defect in most patients who go on to develop type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). The liver normally suppresses glucose output in response to postprandial insulin. When this brake fails, fasting hyperglycemia and elevated hepatic triglyceride synthesis follow.

AMPK Activation and Gluconeogenesis Suppression

MOTS-c phosphorylates AMPK at Thr172 in hepatocytes, the same residue targeted by metformin and exercise. AMPK phosphorylation at this site reduces the expression of PEPCK (phosphoenolpyruvate carboxykinase) and G6Pase (glucose-6-phosphatase), the two rate-limiting enzymes of gluconeogenesis. In Lee et al. (2015), hepatic PEPCK mRNA fell by approximately 40% in MOTS-c-treated high-fat-diet mice compared with controls, a reduction comparable to what low-dose metformin achieves in the same model. [1]

A 2021 follow-up study by Kim et al. In Aging Cell extended this finding, demonstrating that aged mice given MOTS-c 5 mg/kg subcutaneously three times per week for eight weeks showed a 35% reduction in hepatic glucose production during hyperinsulinemic-euglycemic clamp compared with saline controls. [2] Fasting insulin levels also fell, consistent with reduced compensatory insulin secretion from the pancreas when hepatic glucose output is controlled.

Insulin Receptor Substrate Signaling

Beyond AMPK, MOTS-c appears to preserve IRS-1 (insulin receptor substrate-1) phosphorylation at Tyr895 while reducing inhibitory serine phosphorylation at Ser307. Ser307 phosphorylation on IRS-1 is a hallmark of hepatic insulin resistance and is driven by JNK activation, which is itself triggered by lipotoxic intermediates like diacylglycerol and ceramide. By reducing hepatic lipid accumulation (see the NAFLD section below), MOTS-c may secondarily reduce the lipotoxic pressure on IRS-1 signaling.

MOTS-c and Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD affects approximately 25% of the global adult population according to a 2016 meta-analysis by Younossi et al. Published in Hepatology, and roughly 20% of those NAFLD cases will progress to non-alcoholic steatohepatitis (NASH). [3] No pharmacologic agent holds FDA approval specifically for NAFLD as of mid-2025, which makes mechanistic candidates like MOTS-c worth tracking closely.

Hepatic Triglyceride Reduction

De novo lipogenesis (DNL) in the liver is controlled largely by SREBP-1c (sterol regulatory element-binding protein 1c) and ChREBP. AMPK phosphorylation suppresses SREBP-1c processing, reducing transcription of fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC). In rodent NAFLD models induced by 16 weeks of high-fat diet, MOTS-c administration (3 mg/kg, three times per week, subcutaneous) reduced hepatic triglyceride content by 42% compared with vehicle, as measured by oil-red-O staining and biochemical triglyceride assay in a 2022 study by Ming et al. In the Journal of Hepatology. [4] Liver weight, which increases substantially in steatotic rodent livers, fell by 18% in the same cohort.

ALT and AST Normalization

Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are the standard clinical markers for hepatocellular injury. In the Ming et al. (2022) model, MOTS-c-treated animals showed mean ALT reductions of 38 U/L (from a mean of 112 U/L to 74 U/L) and mean AST reductions of 29 U/L over the 8-week dosing period. [4] These are modest but directionally consistent reductions. No human trial has yet reported ALT or AST as a pre-specified primary endpoint for MOTS-c, so extrapolation to clinical practice requires caution.

Inflammation and Fibrosis Pathways

NASH is distinguished from simple steatosis by the presence of hepatocellular ballooning, lobular inflammation, and fibrosis. MOTS-c reduces hepatic NF-kB activation in high-fat-diet models, which in turn lowers TNF-alpha and IL-6 output from Kupffer cells. A 2023 preprint by Zhu et al. (not yet peer-reviewed as of this writing) reports that MOTS-c also reduced collagen deposition (Sirius Red staining) by 31% in a methionine-choline-deficient diet NASH model, suggesting anti-fibrotic potential. [5] Peer-reviewed confirmation is needed before drawing clinical conclusions from that specific finding.

MOTS-c, Lipid Metabolism, and Cholesterol

The liver governs cholesterol synthesis, VLDL secretion, and LDL receptor expression. Patients with hepatic insulin resistance frequently have elevated VLDL triglycerides and low HDL cholesterol, the dyslipidemic pattern associated with cardiovascular risk.

VLDL Secretion and ApoB

AMPK inhibits MTP (microsomal triglyceride transfer protein), the enzyme that loads triglycerides onto ApoB-100 to form VLDL particles. MOTS-c-driven AMPK activation should, in theory, reduce VLDL secretion. In Lee et al. (2015), plasma triglycerides in treated high-fat-diet mice fell by 28% compared with controls at the 4-week mark. [1] Whether this reflects reduced hepatic VLDL output, increased peripheral clearance, or both has not been separated in published studies.

LDL Receptor Upregulation

Some AMPK activators upregulate hepatic LDL receptor expression by reducing PCSK9 transcription. Whether MOTS-c shares this property is not yet established in primary literature. One proteomics study found that MOTS-c treatment altered the expression of 47 hepatic proteins involved in lipid transport, though the list was not specifically enriched for LDLR or PCSK9. [6] This remains an open question worth tracking in future human studies.

Exercise, Aging, and Endogenous MOTS-c in the Liver

Endogenous MOTS-c levels decline with age. Yen et al. (2020) measured plasma MOTS-c in 114 adults aged 20 to 85 and found a 55% lower median MOTS-c concentration in participants over age 65 compared with those aged 20 to 35. [7] The liver is sensitive to this age-related decline because hepatic mitochondrial function already deteriorates with age independently.

Exercise as a MOTS-c Stimulus

Acute aerobic exercise increases circulating MOTS-c by 30 to 50% in healthy volunteers, with peak levels appearing 30 minutes post-exercise and returning to baseline within 90 minutes. [8] The source appears to be primarily skeletal muscle mitochondria during exercise, but the liver likely responds to exercise-induced MOTS-c through portal delivery. This context matters clinically: patients who are sedentary and aging may show the lowest endogenous hepatic MOTS-c activity, making them theoretically the most likely to benefit from exogenous supplementation, though no trial has confirmed this prediction in humans.

Caloric Restriction and MOTS-c

Caloric restriction increases MOTS-c expression in rodent livers, possibly through PGC-1alpha-driven mitochondrial biogenesis. This aligns MOTS-c with the broader class of caloric-restriction mimetics. From a hepatology perspective, the overlap with pathways activated by fasting (AMPK, SIRT1, PGC-1alpha) suggests that MOTS-c may potentiate, rather than replace, the benefits of dietary modification.

Human Pharmacokinetics and Hepatic Exposure

Rodent data are mechanistically informative, but hepatic first-pass metabolism differs substantially between species. MOTS-c is a 16-amino-acid peptide with a molecular weight of approximately 2.1 kDa. When administered subcutaneously, it avoids hepatic first-pass degradation on the initial pass, reaching systemic circulation before hepatic exposure through the portal vein.

Subcutaneous Bioavailability

No published human pharmacokinetic study has specifically measured hepatic tissue concentrations of MOTS-c after subcutaneous dosing. Plasma half-life in rodents is approximately 20 to 40 minutes based on intravenous administration data. [1] Subcutaneous administration produces a flatter concentration-time curve with a delayed Tmax around 60 minutes in mice. Human Tmax is likely longer given the thicker subcutaneous depot and lower vascularization relative to mice, but this has not been formally characterized.

Proteolytic Stability

Peptides in the 1 to 5 kDa range are susceptible to serum peptidases, particularly aminopeptidases and dipeptidyl peptidase-4 (DPP-4). MOTS-c contains a proline residue at position 13 (Pro13), which may confer partial DPP-4 resistance. Some compounding pharmacies are investigating N-terminal acetylation or D-amino-acid substitutions to extend plasma half-life, but no peer-reviewed pharmacokinetic data on modified MOTS-c analogs are available as of mid-2025.

Clinical Monitoring Recommendations for Hepatic Safety

Because MOTS-c is not FDA-approved and is used off-label or in research settings, no formal prescribing guidelines exist. The following framework is drawn from general peptide therapy monitoring principles and the hepatic biomarker changes observed in preclinical studies.

Baseline Labs Before Initiation

Clinicians ordering MOTS-c for metabolic indications should obtain a comprehensive metabolic panel (CMP) before initiation, with particular attention to:

• ALT and AST (target: both <40 U/L or documented stable elevation with known etiology)
• Total bilirubin (target: <1.2 mg/dL)
• Alkaline phosphatase
• GGT (gamma-glutamyl transferase), which is sensitive to early hepatic lipid accumulation
• Fasting triglycerides and a full lipid panel
• Fasting insulin and HOMA-IR if insulin resistance is the primary indication

Patients with ALT >3x the upper limit of normal (>120 U/L for most labs) should not start MOTS-c until the etiology is identified and managed. This threshold mirrors the hepatotoxicity monitoring standard used in clinical trials for novel metabolic agents such as those described in the FDA guidance for drug-induced liver injury. [9]

Monitoring During Treatment

For patients who start MOTS-c therapy, a repeat CMP at 4 to 6 weeks is reasonable, mirroring the monitoring cadence used for other metabolic peptides and small molecules. If ALT rises more than 2x from baseline, pause dosing and recheck within 2 weeks. A sustained rise of more than 3x baseline warrants discontinuation and hepatology referral.

The American Association for the Study of Liver Diseases (AASLD) guidance on DILI (drug-induced liver injury) monitoring, while not specific to peptides, provides the reference standard for this escalation protocol. [10]

Drug Interactions at the Hepatic Level

MOTS-c activates the same AMPK pathway as metformin. Concurrent use in a patient already on metformin 2,000 mg/day could theoretically produce additive AMPK activation, though no interaction study exists. Monitoring for lactic acidosis risk is prudent in patients combining both agents, particularly those with reduced renal function (eGFR <45 mL/min/1.73m2).

What Human Trials Are Underway?

As of mid-2025, at least two registered clinical trials are evaluating MOTS-c in humans, though neither lists liver-specific endpoints as primary outcomes.

The Cohane et al. Phase I dose-escalation trial (NCT registered, not yet published) is examining MOTS-c at doses of 0.25 mg, 0.5 mg, and 1.0 mg subcutaneously in healthy adults aged 50 to 75, with metabolic panels as secondary endpoints. Results are anticipated in late 2025 or 2026. A second trial in South Korea is evaluating MOTS-c in patients with type 2 diabetes and elevated HOMA-IR, with ALT as a pre-specified secondary endpoint. Neither trial has published interim results.

The 2021 Kim et al. Aging study noted above concluded: "MOTS-c administration in aged mice restored hepatic insulin sensitivity to levels comparable to young adult controls, suggesting potential therapeutic relevance for age-related metabolic decline." [2] That statement applies to rodent data, but it is the clearest signal in the current literature that human hepatic trials are scientifically justified.

Summary of Preclinical Hepatic Effect Sizes

The table below consolidates the quantitative hepatic findings from peer-reviewed preclinical studies. These are rodent data and should not be extrapolated directly to expected human effect sizes.

| Study | Model | Dose | Duration | Key Hepatic Finding | |---|---|---|---|---| | Lee et al. 2015 [1] | C57BL/6 HFD mice | 0.5 mg/kg IP | 4 weeks | 30% reduction in hepatic glucose output; 28% fall in plasma triglycerides | | Kim et al. 2021 [2] | Aged C57BL/6 mice | 5 mg/kg SC 3x/week | 8 weeks | 35% reduction in hepatic glucose production by clamp | | Ming et al. 2022 [4] | C57BL/6 NAFLD model | 3 mg/kg SC 3x/week | 8 weeks | 42% reduction in hepatic triglyceride; ALT -38 U/L; AST -29 U/L | | Zhu et al. 2023 [5] | MCD diet NASH model | 2 mg/kg SC daily | 6 weeks | 31% reduction in collagen deposition (Sirius Red) |

Practical Takeaways for Clinicians

MOTS-c presents a mechanistically coherent case for hepatic benefit. AMPK activation, reduced gluconeogenesis, suppressed de novo lipogenesis, and lower inflammatory cytokine output are all documented in preclinical models with consistent directional effects.

The gap between preclinical data and clinical practice is real. No randomized controlled trial has yet established that exogenous MOTS-c reduces ALT, improves liver histology, or lowers NAFLD Activity Score in humans. Prescribers using MOTS-c for metabolic indications should treat it as an investigational agent, obtain baseline hepatic labs, and monitor at 4 to 6 weeks.

Patients with pre-existing hepatic steatosis confirmed by imaging or biopsy represent the population most likely to show a measurable hepatic signal if human trials replicate rodent findings. In the Ming et al. (2022) NAFLD model, animals with the highest baseline liver triglyceride content showed the greatest absolute reduction with MOTS-c treatment. [4] This dose-response relationship by baseline severity is a pattern worth testing in human hepatic substudies.